淋巴缺血与社区获得性肺炎中的广泛宿主反应异常有关
Susanne E Doeleman1, Tom D Y Reijnders1, Sebastiaan C M Joosten1
1Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
The Journal of infection
|March 2, 2024
概括
患有淋巴缺血性社区性肺炎 (CAP) 的患者经历了更长的恢复时间和更受损的免疫反应. 这突显了CAP患者低淋巴细胞计数的预后意义.
科学领域:
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
- 关键护理医学 关键护理医学
背景情况:
- 淋巴缺血症 (淋巴细胞数量低) 影响超过三分之一的社区获得性肺炎 (CAP) 患者在入院时.
- 淋巴缺血性CAP (L-CAP) 的临床意义和潜在的免疫机制尚不清楚.
研究的目的:
- 调查L-CAP.患者的临床结果和免疫特征.
- 将L-CAP定义为入院时的淋巴细胞数量低于0.724×109细胞/L.
主要方法:
- 149名接受CAP治疗的患者进行了观察性研究.
- 测量了34个与炎症,内皮功能,凝血和免疫检查点相关的血生物标志物.
- 使用光谱流细胞计,对29名患者的淋巴细胞子集进行了表征.
主要成果:
- 在30.2%的患者中发现了L-CAP,并且与显著延长的临床稳定时间 (5天而不是3天) 有关.
- 在L-CAP患者中,CD4 T毛囊辅助细胞,CD4 T效应记忆细胞,天真CD8 T细胞和IgG+B细胞的水平降低.
- 生物标志物分析显示,L-CAP中细胞因子网络和血管内皮的激活增加.
结论:
- 患有L-CAP的患者表现出延迟的临床恢复和宿主免疫反应更普遍的失调.
- 在CAP中,入院淋巴缺血是预后相关的,并表明复杂的病理生理过程.
相关概念视频
Pneumonia I: Introduction
236
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
236
Pneumonia II: Pathophysiology
269
The pathophysiology of pneumonia involves the following steps:
269
Pneumonia III: Complications and Assessment
209
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
209
Disorders of Leukocytes
950
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
950
Factors Affecting the Risk of Infection
11.8K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
11.8K
Pneumonia IV: Management
324
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324


